Enhancing the structural stability of P29-targeted monoclonal antibodies via β-hydroxybutyrylation modification improves their therapeutic performance in alveolar echinococcosis.

Following intravenous administration in C57BL/6 mice (n=5/group), longitudinal monitoring of serum concentrations by ELISA demonstrated that P29 mAb kbhb maintained slightly elevated levels over the unmodified antibody during the initial 1–4 weeks, though these differences did not reach statistical significance.

also in 111,027 other papers